Tryptamine Therapeutics (AU:TYP) has released an update. Tryptamine Therapeutics, a biotech company listed on ASX, announced the results of its 2024 Annual General Meeting, where all resolutions ...

Rockville, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- According to a new industry report by Fact.MR, the global tryptamine API market is projected to be worth US$ 757.2 million in 2024 and thereafter ...

Tryptamine receives firm commitments to raise $6m in placement strongly supported by new and existing stakeholders Placement cornerstoned by Merchant Biotech Fund and biotech investor Dr Daniel ...

Followed categories will be added to My News. Tryptamine receives firm commitments to raise $6m in placement strongly supported by new and existing stakeholders Placement cornerstoned by Merchant ...

Tryptamine’s IV-infused psilocin formulation TRP-8803 ‘generally safe and well tolerated’ Findings are from Safety Review ...

Tryptamine Therapeutics (AU:TYP) has released an update. Tryptamine Therapeutics Limited (ASX: TYP) has requested a trading ...

Don't miss out on the headlines from Stockhead. Followed categories will be added to My News. In this episode, host Fraser Palamara dissects the $6 million raising completed today by biotech ...

Tryptamine Therapeutics (AU:TYP) has released an update. Tryptamine Therapeutics is undergoing a strategic board reshuffle as Non-Executive Director Peter Molloy steps down, paving the way for Dr ...